Background and Objective: The management of rare tumors is difficult because of limited information on natural history. Our objective was to describe a long-term comprehensive prospective database with the assumption that with careful attention to patient, predisposing tumor and treatment variables, valuable knowledge could be obtained that could guide management. Methods: In July of 1982, we began a prospective database of all adult patients admitted to our institution for a surgical procedure for soft tissue sarcoma. Patients were included if they had primary, locally recurrent or metastatic disease undergoing a surgical procedure. Results: Over 3 decades, we entered 10,000 patients into our prospective soft tissue sarcoma database. Data were entered on a weekly or biweekly schedule with full participation of a multidisciplinary team and a dedicated sarcoma pathologist. Extensive information is available from this database. In this article, we describe distribution by site, histopathology, sex, size, and grade. We utilize this information along with outcome data for local recurrence, distant recurrence, disease specific, and overall survival. The value of molecular diagnosis is illustrated. Conclusions: Continuous prospective long-term databases are important to obtain knowledge particularly for rare tumors. Such data can be a rich resource for the development of prognostic indicators including nomograms and can be analyzed by Bayesian Belief Networks. These long-term data linked to collection of tumor and germ-line tissue at the time of an initial procedure will remain a resource for future decades. others continuing with multiple recurrences or late recurrences over decades.
T he ability to define outcome and thereby design management approaches for rare malignancies is extremely difficult. Soft tissue sarcoma is a group of diverse malignancies with variable presentation, behavior, and outcome. Soft tissue sarcomas are complicated by the fact that they represent at least 80 potentially malignant histological types and subtypes; of these, 50% are fully malignant and commonly metastasize and 50% are locally aggressive with some but limited metastasis potential. Most soft tissue sarcomas are believed to be sporadic; however, in a small proportion of cases, genetic factors, lymphedema, and prior radiation therapy have been identified as predisposing or associated factors. Sarcomas display varying degrees of mesenchymal differentiation, making diagnosis and behavior prediction difficult. 1 This problem is compounded by the nature of these diseases, some with early progression, recurrence, and demise, and
MATERIALS AND METHODS
In July of 1982, we began a prospective inpatient database of all adult (older than16 years) patients admitted to our institution for the surgical management of soft tissue sarcoma. This includes patients presenting with primary, locally recurrent, or metastatic disease, if they were to undergo a surgical procedure. Patients who were seen in consultation or patients who were never admitted for a surgical event were not included. This was a deliberate decision given the difficulty of following the multitude of patients who were referred for second opinion and/or outpatient treatment. The decision was made to include inpatients undergoing surgical procedures, so there would be ready availability of tissue for clear definition of histological type and subtype. Careful classification of other patient, tumor, and treatment characteristics was prospectively recorded. In addition, we were able to obtain at the time of presentation consent for collection of not only tumor but also adjacent normal tissue and in later years, blood for germ line analyses. Data are entered and reviewed by the sarcoma disease management team at the time of inpatient admission, initially weekly and then biweekly, with all tumor samples classified for histological type, subtype, and grade (low vs high) by a dedicated sarcoma pathologist and recorded in an ongoing prospective database. The pathologic features that were used to define grade included mitotic index, necrosis, cellularity, pleomorphism, and histologic type and subtype or differentiation. Snap frozen tissue was banked from surgical specimens and the tissue type and freezer location was recorded in the database and directly linked to patient, tumor, treatment, and outcome variables. Patients were followed for local recurrence, systemic recurrence, disease-specific, and overall survival. An automated system was initiated whereby if a patient entered into the database returns to the institution, the follow-up note is automatically delivered to the sarcoma data management team. Patients who had no follow-up in the 6 months since last recorded were identified by dedicated reports such that follow-up could be obtained in a timely fashion.
Any predisposing or associated factors including underlying genetic diseases, such as neurofibromatosis, heritable retinoblastoma, or Li-Fraumeni syndrome, or history of radiation exposure or the presence of lymphedema, all known to be associated with causation are carefully documented. Such databases are, however, not static as new entities are described and histological classification evolves through identification of subtypes that more precisely define tumor biology and patterns of behavior. Recent advances in the molecular, genetic, and cytogenetic characterization of soft tissue sarcoma have improved and refined diagnosis and etiology.
For this presentation, we focus on distribution and outcome by body site, size and depth, the influence of grade and histology, and utilization of combined prognostic variables for prediction of outcome. We describe the consequences of local recurrence and the influence of molecular characterization on diagnosis and management.
RESULTS
From July 1982 until May of 2013, we entered 10,000 patients into our prospective soft tissue sarcoma database. Approximately 40% of lesions occur in the extremities, 38% in visceral or retroperitoneal areas, and the remainder is distributed throughout the body ( Table 1) . The distribution of lesions throughout the extremities is demonstrated in Figure 1 , with the thigh being the dominant site, presumably based on the volume of soft tissue present. Distribution by sex, size, and grade is shown in Table 1 . Primary size is not accurately known in some patients who present for a surgical procedure for local or metastatic recurrence. For grade, we have excluded gastrointestinal stromal tumors (GIST), which are not graded but characterized by size and mitotic rate.
Site is a major determinant of outcome and pattern of recurrence. Retroperitoneal and intra-abdominal lesions have a propensity for early local recurrence, with approximately 50% recurring within the first 5 years, followed by a continuous and relentless progression extending out for more than 20 years ( Fig. 2 ). Extremity and visceral lesions have approximately a 20% to 25% local recurrence rate at 10 years, but in all sites, late (>10 years) local recurrence continues to occur, emphasizing the need for prolonged follow-up, as local recurrence can occur more than 2 decades from initial diagnosis. These data give an important description, not only of outcome but also of biology and patterns of behavior. If we examine disease-specific survival, that is, death from disease, then the pattern is quite different between visceral and extremity lesions ( Fig. 3 ). Extremity lesions with a local recurrence rate of approximately 25% at 10 years have a disease-specific death prevalence of approximately 40% at 10 years, emphasizing the importance of systemic disease as the cause of death. Retroperitoneal and intra-abdominal lesions, whose local recurrence is relentless extending out for more than 15 years and exceeding 60%, have a pattern of disease-specific survival that is similar to the pattern of local recurrence, although with some smaller contribution of metastatic disease. Most dramatically, visceral lesions with a local recurrence of less than 20% at 10 years have a disease-specific survival of approximately 35% at 10 years, emphasizing that the majority of these deaths occur from systemic disease. The database has, in effect, given us information about biological behavior and pattern of recurrence and overall outcome, that is, death for extremity and visceral lesions is predominantly systemic, whereas in retroperitoneal and intra-abdominal lesions, the dominant cause of disease-specific death is local progression, albeit often with multifocal local progression.
Two of the most important predictors of outcome are histology/ histologic subtype and grade. For some sarcoma types, histologic type defines grade with synovial sarcoma, rhabdomyosarcoma, and Ewing sarcoma, all classified as high grade. For liposarcoma, histologic subtype defines grade with well-differentiated and myxoid liposarcoma considered low grade and dedifferentiated, round cell, and pleomorphic liposarcomas classified as high grade. 2, 3 The distribution between high and low grade (∼2:1) is seen in Table 1 . Grade is a powerful predictor of outcome. If we examine only those patients presenting with a primary (ie, treated first at our institution) lesion of the extremity, there was an approximately 20% local recurrence rate at 10 years for both low-and high-grade lesions ( Fig. 4) , whereas disease-specific survival is highly influenced by the grade of the primary tumor (Fig. 5 ). Systemic recurrence is uncommon in low-grade lesions (<10%) at 20 years, whereas in high-grade lesions, death from disease is about 40% at 10 years. Again, late (>10 years) systemic recurrence and death from disease can occur in both high-and low-grade lesions. Of interest, many of the initial low-grade lesions that do recur systemically may recur with high-grade characteristics. Size and depth are known variables that can influence outcome. These are not necessarily independent as it is unlikely that one would have a large superficial tumor whereas the majority of deep tumors can be expected to be at least 5 cm in maximal dimension. The simple distribution of primary size is shown in Table 1 for all grades and presentations (primary, local, and systemic recurrences). Outcome by size alone is shown in Figure 6 for 1808 patients with high-grade tumors. Patients with extremity lesions larger than 10 cm in size have a disease-specific survival of less than 40% at 15 years, and late recurrence and death are once again seen. This has important distinctions for staging systems in which size is classically divided between smaller than 5 cm and larger 5 cm. The combination of depth and size is illustrated in Figure 7 for primary extremity high-grade lesions alone, emphasizing the powerful impact of size relatively independent of depth once the lesion reaches 5 cm and emphasizing the relative rarity of large (>5 cm) superficial lesions where they make up only 8% of all larger than 5 cm lesions.
Distribution by histology is shown in Table 1 and distribution of histopathology by site is illustrated in Figure 8 , emphasizing the site-dependent relationship with histopathology. This is then reflected by the dependence of site of initial or dominant metastasis on the site of the primary lesion ( Fig. 9 ). An excellent example is the dominance of lung for primary extremity site, and the predilection of uterine leiomyosarcoma for lung in contradistinction to GIST, which is primarily to liver. The implications for surveillance in follow-up are obvious.
Histology is a variable that with progressive time and definition becomes more precisely defined. A good example is visceral leiomyosarcoma, many of which were reclassified as GIST after the discovery in the late 1990s of activating mutations in KIT and PDGFRA, specifically in GIST. This provides awareness that such databases, in which the inherent data may change, will become more variable. Such databases must be considered to be living and adapting entities.
The diagnosis of soft tissue sarcoma has been revolutionized by the recognition of molecular diagnostic signatures. This is not only seen in many of the Ewing family of tumors but also applicable to multiple other histological subtypes. 1 A prime example is synovial sarcoma characterized by the t(X;18)(p11.2;q11.2) chromosomal translocation in nearly all cases. Previously thought of as a tumor that affected adolescents and young adults, it is now quite clear that this tumor can occur throughout life (Fig. 10 ). More importantly, in the past regarded as a tumor that occurred in the extremities in and around joints, it is now clear that it is not derived from synovium, although the specific cell type is unknown and the tumor has been identified in multiple other unusual sites such as the head and the neck (fewer than 10%), thoracic and abdominal wall (fewer than 10%), or intrathoracic sites. We have identified such lesions in especially unusual sites such as the heart, the prostate, and the diaphragm.
Lymph node metastases in soft tissue sarcoma are rare. 4 When lymph node metastasis occurs in the absence of other metastasis, some patients can be rescued (Fig. 11 ). However, combination of the presence of a lymph node metastasis and other metastases is a poor prognostic sign.
DISCUSSION
The present report highlights the advantages of having large focused prospective databases in tumor entities that are rare. Such data sets can be utilized not only for the prediction of prognostic factors, 3, 5, 6 but also for the identification of varied and variable prognostic events at the time of presentation that influence the type of recurrence, that is, disease-specific survival, metastasis-free survival, or overall survival. Most importantly, they provide a stable description of patient-specific outcomes in a series of rare diseases, giving a baseline for predicted outcome and risk. Such identification of prospective variables can then be utilized in appropriate stratification in randomized controlled trials. 6 We have taken these data to describe patient-specific predictive nomograms for outcome. 7 The development of such nomograms is absolutely dependent on validation by other databases both nationally 8 and internationally. 9 Databases are best constructed if the data set is large, events positive and negative, for example, alive or dead, relatively equally distributed, and the follow-up is long. Sarcoma has been an excellent source for such data sets and we have adapted these to predict local recurrences, 10 predict survival after local recurrence, 11 and apply to unique histopathologies such as liposarcoma, 12 GIST, 13 synovial sarcoma, 14 and the desmoid tumor. 15 Such data sets are a rich tool required for the development of other mathematical models, utilizing other statistical techniques such as Bayesian Belief Networks. 16 An important observation is the value of such databases in defining surveillance in follow-up. An awareness of the primary or first site of metastasis, lung as shown for extremity lesions and liver for GIST, can focus follow-up imaging to a single site reserving further imaging for those found to be positive in the dominant site.
We have previously commented and documented the consequences of local recurrence. Clearly, an early large local recurrence is accompanied by a much poorer prognosis than a late small recurrence, particularly if the initial recurrence is of high grade and the late recurrence is low grade. 17 However, as we illustrated here and in a prospective randomized trial, 5 diminution of local recurrence does not translate into a disease-specific survival benefit, an important principle; local recurrence is associated with, but has limited if any causative effect on disease-specific survival.
Molecular diagnosis has been an extraordinary advance as we have demonstrated using synovial sarcoma as an example. Synovial sarcoma, previously thought of as an entity that occurred in adolescents and young adults in and around joints of the extremity, has now been characterized by a recurrent SYT-SSX fusion gene. 18 The identification of this fusion gene by molecular diagnosis 19, 20 has resulted, as shown here, in the identification of such tumors in patients throughout life, albeit with a predilection for adolescents and young adults. Not only has the age spectrum been better defined, but unusual sites previously not conceived of as being associated with "synovium" have been characterized. This in itself emphasizes the absence of knowledge of the cell of origin for "synovial sarcoma" but clearly not from synovium. This identification of molecular signatures in sarcoma and other rare tumors becomes a potential for therapy. If a tumor can be shown to express a mutated gene as an oncogene or tumor suppressor gene such as p53 or an exaggerated expression of a particular gene that acts as a driving mutation, the potential for therapy is obvious. This is well described in the identification of the c-kit mutation in GIST. The identification of this mutation and the ability to take a tyrosine kinase therapeutic inhibitor such as imatinib transformed the management of these tumors. Historically, 21 the ma-jority of such patients progressed to early demise. With the advent of a selected directed therapy, not only was survival prolonged in the presence of advanced and metastatic disease, 22 but the agent could be utilized in randomized trials as an adjuvant therapy after surgical excision. 23 With increasing knowledge, it has become clear that each selective drug acted presumably against or at least preferentially against one mutation but not others as is seen in the difference between response to the mutated exon 9 and the mutated exon 11 of the c-kit gene. 24, 25 As we have also shown here, such databases can become remarkable tools for examining prognostic indicators. Not only can patient-specific nomograms be identified but the data set can be examined for other associations utilizing such tools as Bayesian Networks. 16 In this situation, even in the absence of complete data on every patient, one can look for associations mathematically that may not have been anticipated when one thinks purely in the context of prognosis. As we have also shown, these data can provide the basis for predictive tools that can be further examined for the impact of the significance of surface antigens, molecular targets, or even therapy. One can suggest that if the quality of the predictive outcome has very little variance and one intervenes with a therapeutic event, such that the observed outcome far exceeds any confidence limits of the predicted outcome, we can argue for a therapeutic effect. If this could be demonstrated, then we would have a tool to utilize in rare and unusual tumors where randomized controlled trials are essentially not possible. Conversely, it does require data sets of rare tumors that are large and followed for a long period of time.
New targeted therapies are desperately needed for the approximately 6000 patients who die each year in the United States of sarcoma. 26 A key challenge will be to identify the alterations that drive sarcomagenesis for each subtype of sarcoma so as to identify subtype-specific targets for therapy. To achieve this goal, our group performed an integrative analysis of DNA sequence, copy number, and mRNA expression in 207 samples encompassing 7 major sarcoma subtypes that were linked to the clinical data from the prospective database. Frequently, mutated genes included TP53 (17% of pleomorphic liposarcomas), NF1 (10.5% of myxofibrosarcomas and 8% of pleomorphic liposarcomas), and PIK3CA (18% of myxoid/roundcell liposarcomas). PIK3CA mutations in myxoid/round-cell liposarcoma were associated with Akt activation and poor clinical outcomes. CDK4 and YEATS4 were found to be amplified and overexpressed in dedifferentiated liposarcoma and drivers of liposarcoma proliferation in functional screens performed in dedifferentiated liposarcoma cell lines. 27 Microarray analysis of liposarcoma samples for gene expression has been linked to the clinical database and used to derive a multigene predictor of distant-recurrence free survival and identify genes driving liposarcoma progression. 28 This gene expression data set demonstrated that well-differentiated and dedifferentiated liposarcoma have activation of cell-cycle and checkpoint pathways, including the upregulation of CDK4, MDM2, CDK1, CDC7, TOP2A, PRC1, PLK1, and cyclins B1, B2, and E2. 29, 30 Therefore, these pathways may be useful as therapeutic targets. In fact, nutlin-3a, a selective MDM2 antagonist, induces apoptosis and inhibits proliferation of dedifferentiated liposarcoma cell lines at concentrations that do not affect normal adipose-derived stem cells. 29 Furthermore, PD0332991, a selective CDK4/CDK6 inhibitor, inhibits proliferation by inducing G1 cell-cycle arrest and senescence in dedifferentiated liposarcoma cell lines and xenografts. 27 In a recent phase II trial of PD0332991 in patients with advanced CDK4-amplified liposarcoma, 66% of patients were progression-free at 12 weeks, and a subset had a radiographic response and prolonged stable disease. 31 These results provide a rationale for use of MDM2 antagonists and CDK4 inhibitors in patients with well-differentiated and dedifferentiated liposarcoma and show the value of tissue and cell line resources linked to clinical and pathological factors for the discovery of new subtype-specific targeted therapy.
The situation can be expanded to where more extensive genetic or array analysis can then provide further mathematical models 32 looking at significant functional events such as copy number alterations or mutations that begin to dissect the activated signaling pathways by which tumors are driven to grow. With that analysis, we then begin to see patterns of expression that identify tumors from far different sites, for example, head and neck versus ovary, which would not have been conceived to be in any way biologically similar. This approach is the next step after the transition from an awareness that in malignancy treatment has become disease-specific and not organ-specific or discipline-specific. Now, we can conceive different lesions in different sites in the body even with different histological appearance that reveal pathways of progression and growth that can be inhibited independent of the site of origin of the tumor.
DISCUSSANTS

Dr. R. Pollock (Columbus, OH):
Drs. Brennan, Singer, and colleagues are responsible for a remarkable contribution to our understanding of a rare and devastating disease. Through their efforts spanning more than 30 years, the group at Memorial Sloan Kettering Cancer Center, more than any other single institution, has educated us about the natural biology of soft tissue sarcoma.
Dr. Brennan has described the database as a dynamic entity. Linked as it is to a comparably large sarcoma tissue repository, clinical annotation of tumor and peripheral blood samples has been possible and has led to a robust stream of funding mechanisms to pursue molecular insights, including a sustained sarcoma NIH sarcoma PO-1 program and 1 of 2 NIH/NCI-funded sarcoma SPORE grants.
As we embark on the transition to incorporate molecularderived information into our understanding of sarcoma and other malignant entities, this database will predictably emerge as critical to such efforts, as per its dynamic nature. This expanded molecularbased awareness, to be truly useful, mandates that such data will be delineated and displayed with the same level of inclusivity and research accessibility as has been championed by Dr. Brennan for more than 3 decades.
Given this emerging reality, a question is perhaps worthy of consideration.
Gene array-derived information is primarily descriptive at this point. A given gene is either mutated or it is not, cognate proteins are either over-or underproduced, said proteins are either phosphorylated or not, and so forth. A gene array can inform us of the frequency and specificity of a given mutation and the fold-amplitude of resultant protein over-or underexpression. Gene copy number, proteomic, and even metabolomic data are already emerging as prognostically relevant. Much of the power of these new molecular insights will be dependent on leveraging the interaction and connectivity of these variables in both a biological and statistical sense. Waterfall diagrams, quantifiable dot blots, and other new informatics for molecular display and manipulation are coming forth on a near daily basis.
The core of my question is how, Dr. Brennan, do you envision that this individual tumor-specific profile of molecular abnormalities will be initially captured to the database and then potentially revised as additional molecular characterizations emerge, for example, the incorporation of TCGA soft tissue sarcoma data that will reach analytic maturity over the next relatively short time interval?
Response From M.F. Brennan:
I failed to show my last slide, which was an acknowledgment of our grant support and, of course, the acknowledgment of the 10,000 patients that participated in these studies.
Dr. Pollock asks all the right and very challenging questions. Most importantly, questions that could not have been answered just 10 years ago.
I hope I showed you that, as a diagnostic tool, genetic information now defines diseases in a way that we could not possibly do. We have clearly demonstrated, I hope, that in synovial sarcoma without that fusion gene being present, we don't make the diagnosis, which means that we make it in much different situations than a few years ago.
The challenge, as Dr. Pollock points out, is how do we take these data, not just genetic signatures but actual pathway signatures, and integrate that into our management?
We have recently a number of studies, led by the senior author, Dr. Sam Singer, that have looked at actual pathways within these tumors. Others, with the use of computational biology, have done the same for multiple cancers. And now we can describe cancers that we would have thought were very different, such as head and neck and ovary, that have the same exaggerated mutations.
I alluded at the end to the key issue that Dr. Pollock raises: how do we take that data and no longer define cancer as a site-specific or a histology-specific but as a pathway-specific event? Targeted therapy can then be directed at a driver or sustaining mutation turning cancer into a chronic disease.
How to incorporate that incredible amount of information into a database is very difficult and is a challenge we currently pursue.
